Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy AMB25-AHS-C-00023-SC

    Ambetter Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for Centene Policy AMB25-AHS-C-00023-SC alerts

    Get alerted when Policy AMB25-AHS-C-00023-SC changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the Ambetter prescription drug formulary (2026) describing covered drugs, tiering, utilization management (prior authorization, step therapy, quantity limits), specialty drug handling, and opioid limits for members and providers under Centene's Ambetter plans.

    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-SC
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProviders must complete the Prior Authorization form and submit necessary clinical and quantity documentation for PA-required drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026Formulary year
    7-day limitOpioid restriction
    many agentsPA prevalence
    Tier 0-4Tiers described

    Coverage Rules and Formulary Tiering

    General Coverage and Tiering

    Formulary coverage and tiering

    Formulary tiering and preferred options: Generics are first-line when available; preferred brand drugs are typically listed on Tier 2. Tiers 0–4 determine member cost-sharing and specialty drugs (Tier 4) may require specialty pharmacy handling.

    Not all dosage forms or strengths may be covered; plan-specific benefit designs may further limit coverage.

    Opioid Limits

    Opioid prescribing limits for new starts

    Opioid new-start limits: New opioid starts are limited to a 7‑day supply. Members may receive up to two 7‑day fills during any 28‑day period, with a cumulative maximum of 28 non‑consecutive days' supply in any 90‑day period. Fills exceeding these limits require prior authorization.7‑day fills; max 28 days in 90

    Limit applies cumulatively to all opioid medications filled.

    Formulary product-level coverage rules

    Coding, Quantity Limits, and Examples

    Formulary Flags and Limits (examples)mixed
    QL(1 EA daily)Quantity limit examples shown (various products)
    AL(At least yrs old)Age limits examples shown (various products)
    PAPrior Authorization flag shown for specific products
    STStep therapy flag shown for specific products
    SPSpecialty tier flag shown for specific products
    Formulary entries (no billing codes)mixed
    N/ANo explicit CPT/HCPCS/ICD-10 codes present in this excerpt; only drug product names, tiers, QL, PA, AL and package limits are shown.
    Formulary restrictions and administrative codesmixed
    QL(4 EA daily)Example quantity limit cited for certain opioid products
    QL(2 EA daily)Example quantity limit cited for certain opioid products
    QL(0.146 ML daily)Example quantity limit for injectable/ML formulations
    PAPrior authorization required (abbreviated in entries)
    No explicit CPT/HCPCS/ICD-10/NDC codes presentmixed
    No codes listed
    Opioid new-start supply limits — concise rules
    Opioid new-start supply limitNew opioid starts limited to a 7‑day supply; up to two 7‑day fills allowed during any 28‑day period; cumulative maximum of 28 non‑consecutive days' supply in any 90‑day period (fills beyond require prior authorization)
    Applies to

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior Authorization (PA) is required for products that are flagged 'PA' in the formulary. Providers must complete and submit the payer's Prior Authorization form and supply clinical documentation supporting medical necessity (diagnosis, indication, prior therapies tried, patient age when an age limit applies, and the requested quantity/days supply). Urgent PA requests will be responded to within 24 hours of receipt of all necessary information; non-urgent requests will be responded to within 72 hours unless state law requires a faster response. If a request is disapproved or incomplete, the notice will state specific reasons for denial or identify the missing information required to complete the request.

    • Complete the Centene/Payer Prior Authorization form and include clinical justification (indication, prior treatment, labs or diagnostic info as applicable).
    • Indicate patient's age when AL (age limit) is listed and the specific quantity/days requested when QL (quantity limit) applies.
    • Allowable PA response times: urgent = 24 hours; non-urgent = 72 hours (subject to state law).
    • Denial notices will explain specific reasons or missing information.
    Prior Authorization

    Initial Therapy Restrictions and Start Rules

    Initial therapy restrictions (examples)

    Some products include age and step restrictions for initiation.

    Example initial therapy restrictions: OTEZLA entries include age limits (AL: at least 45 years old up to 79 years old), PA and package‑per‑180‑days restrictions for some presentations. Many opioid products indicate 'New starts limited to 7 day supply' as an initiation restriction.AL(At least 45 yrs); New starts = 7 days

    These are example initial therapy constraints pulled from formulary lines; check the specific product line for exact initiation rules.

    Initial therapy limits

    Initial therapy rules present in this excerpt

    Initial opioid prescribing restrictions: For initiation of many opioid products, 'New starts limited to 7 day supply' is applied. Certain formulations also require PA and have per‑day QL values; documentation supporting continuation beyond initial limits requires prior authorization.

    Continuation and Renewal Considerations

    Continuation therapy (not specified)

    Continuation/ongoing therapy considerations appear implied by 'new starts' restrictions but specific continuation criteria are not provided in this segment.

    Continuation implied: Products initially limited to a 7‑day supply may have different continuation rules not specified here; continuation beyond initial fills generally requires documentation or prior authorization as indicated on product lines.

    No explicit continuation criteria are present in the provided excerpt; refer PA process for continuation exceptions.

    Step Therapy Flags and Examples

    ProductFormulation / PresentationStep Therapy (ST) flagNotes
    Lisdexamfetamine dimesylate CAPS / CHEW presentations
    ST present on some presentations; QL values shown (e.g., QL(1 EA daily), QL(6 EA daily))
    Step therapy flag present (documented as 'ST' in Drug Requirements/ILimits)
    See formulary lines where ST is indicated for stimulant class entries
    Requested DrugRequired Prior StepST FlagSource note
    Must try ibuprofen prior to approval
    Documented as the required trial agent in the Drug Requirements/ILimits field
    Entry shows 'Must try ibuprofen' associated with ST
    ACTEMRA SOLN 80 MG/4ML — 'Must try ibuprofen: QL(5...' (see formulary)
    ScopeDetailST sequences provided?Comment
    Multiple entries list tiers and ILimits
    No explicit multi-step sequences are provided in this excerpt
    Tiers and flags imply preferred agents but do not enumerate ordered steps
    Refer to full formulary policy for full ST algorithms
    Drug / ClassTierST implicationNotes
    Tier 1B–2
    Placement on Tier 2–3 suggests preferred lower-tier inhaled agents should be tried first
    May imply step before coverage of higher-tier combinations though explicit ST rules not enumerated here
    See inhaled corticosteroid/bronchodilator entries with tiering and ILimits
    Product / ExamplePA present?QL present?Notes
    PA
    PA; QL(20 ML daily)
    PA; QL(0.25 ML daily) / QL(0.0714 ML daily)
    PA and QL are specified on many lines even where no step algorithm is shown

    Quantity Limits (QL) — Product Examples

    Multiple stimulant and related products — assorted QL examples
    Stimulant product QLsExamples include QL(1 EA daily), QL(2 EA daily), QL(3 EA daily), QL(280 ML per 56 days)
    Patch/long‑acting examplesmethylphenidate patches and extended‑release lines show per‑period QLs (e.g., 280 ML per 56 days)
    Age/PA interplayMany stimulant entries include AL and PA alongside QL (check product line for specifics)
    Opioids (new starts) — detailed new‑start supply limits
    New‑start supply rule (detailed)New starts limited to a 7‑day supply; allow up to two 7‑day fills during any 28‑day period; up to 28 non‑consecutive days' supply in any 90‑day period; fills beyond these limits require Prior Authorization
    Cumulative application

    Specialty Pharmacy, Retail vs Mail, and Site Restrictions

    Billing Rule

    Route SP drugs to Ambetter specialty/hemophilia network

    Specialty tier drugs may be required to be dispensed through Ambetter's specialty or hemophilia network pharmacies; when SP is indicated, route prescriptions to the appropriate network pharmacy and note this in the PA.

    • Tier 4 specialty drugs may require fulfillment at Ambetter specialty/hemophilia network pharmacies.
    • Confirm specialty pharmacy routing in the PA submission.
    Note
    Note

    Biosimilars and Package Limits

    Prior Authorization

    Provide package, dosing, and PA for adalimumab biosimilars

    Multiple adalimumab biosimilars are listed with QL and PA and package limits per 180 days; when prescribing biosimilars, include package count, dosing, and request PA as needed to meet the formulary constraints.

    • ADALIMUMAB biosimilars list QL(0.143 EA daily) and package(s) per 180 day(s); PA is required.
    • Document exact presentation (pen/syringe), package count and intended fill interval in PA submissions.

    Glossary and Acronyms

    Policy Background and Scope

    The Ambetter Formulary is a prescribing guide that promotes generic medications as first-line when available and distinguishes preferred brand versus non-preferred products by tier. It is not an exhaustive list: not all dosage forms or strengths may be covered, the list is periodically updated, and specific plan benefit designs may exclude certain products or categories despite appearance on the formulary. Providers and billing staff should confirm member-specific benefits and cost-sharing before assuming coverage.

    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-SC
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProviders must complete the Prior Authorization form and submit necessary clinical and quantity documentation for PA-required drugs.
    SourceLink
    On This Page
    Coverage Rules and Formulary TieringCoding, Quantity Limits, and ExamplesPrior Authorization, Step Therapy, and Documentation RequirementsInitial Therapy Restrictions and Start RulesContinuation and Renewal ConsiderationsStep Therapy Flags and ExamplesQuantity Limits (QL) — Product ExamplesSpecialty Pharmacy, Retail vs Mail, and Site RestrictionsBiosimilars and Package LimitsGlossary and AcronymsPolicy Background and Scope

    Coverage entries in this excerpt are largely formulary rules tied to specific products and presentations.

    Formulary coverage entries: Each product presentation is described with Tier assignment and Drug Requirements/ILimits fields that may include QL (quantity limit), PA (prior authorization), AL (age limit), package or max‑fill rules, and specialty (SP) designations.

    Clinical medical‑necessity criteria are not enumerated in this excerpt; coverage is governed by the listed administrative constraints.

    Formulary Coverage Constraints (partial)

    Coverage entries include per-product rules; many opioid and combination products are covered subject to the following constraints

    Per-product coverage constraints: Product coverage is conditional on meeting the formulary line requirements: tier assignment, quantity limits (QL), age limits (AL) where indicated, step therapy (ST) where indicated, and prior authorization (PA) when listed. Many opioid and opioid‑combination entries include the statement 'New starts limited to 7 day supply'.See per‑product QL/AL values

    Providers should consult the specific product line for exact QL, AL, ST, PA or SP flags.

    Formulary tiering and limits (sample)

    Coverage and utilization management entries (select examples from excerpt):

    Sample tiering and limits: Selected therapeutic classes and combination antihypertensive products are assigned tiers (1A/1B/2/3) and may have per‑line QL or PA requirements; specific combination products show QL ranges (e.g., benazepril & hydrochlorothiazide listed with QL values across entries).Refer to product line QL values

    These examples illustrate how tiers and QL/PA interplay to govern coverage.

    XIFAXAN utilization criteria

    Anti‑infective specific coverage constraints:

    XIFAXAN utilization criteria: XIFAXAN 200 mg and 550 mg presentations include utilization controls. XIFAXAN 200 mg: QL = 3 tablets (9 tablets per 3 days retail; 9 per 3 days mail); AL = at least 12 years old; PA required. XIFAXAN 550 mg: listed with PA and age information in the formulary line.Age >= 12 for XIFAXAN 200 mg; QL as specified per product

    Providers must meet age and PA requirements and adhere to stated QL for coverage.

    Malaria treatment coverage limits

    Antimalarials:

    Atovaquone‑proguanil (malaria) limits: Atovaquone‑proguanil is covered for malaria treatment only. Quantity limits apply (e.g., QL = 12 tablets per fill retail or mail) and a maximum of 1 fill every 180 days; prior authorization may be required for some presentations.1 fill per 180 days; QL(12 EA per fill)

    Limit is expressed as 'Limit 1 fill every 180 days' in the formulary lines and applies across listed formulations.

    Antineoplastics coverage constraints

    Antineoplastics and adjunctive agents:

    Antineoplastic requirements: Many antineoplastic agents are assigned specialty or Tier 4 status and include utilization controls such as SP (specialty processing), PA (prior authorization), and/or QL (quantity limits). Examples: cisplatin, busulfan, melphalan, oxaliplatin and others list SP; PA or PA and specific QL values.

    Specialty handling and prior authorization are commonly required for oncology agents; consult the product line for exact ILimits.

    Covered with formulary controls

    Coverage with utilization management per formulary annotations

    General formulary conditions: Drugs are covered consistent with their tier when the formulary conditions are met: quantity limits (QL), age limits (AL), prior authorization (PA), step therapy (ST), and specialty pharmacy routing (SP) as indicated per product line. Failure to meet listed requirements may result in claim denial or require PA submission.

    Apply the ILimits and flags shown on the specific formulary entry for adjudication.

    General coverage rules for listed topicals

    Coverage is defined by formulary tier plus any of the following constraints:

    Topical product coverage rules: Topical agents are covered according to their tier assignment and must meet any listed constraints: AL (age limits), QL (quantity limits), PA (prior authorization), and ST (step therapy) where shown. Example: topical clindamycin formulations include AL and QL and some formulations require PA; certain products have 'Limit 1 Fill per 180 days.'See product ILimits per formulary line

    Prescribers should document indication, age and requested quantity to support coverage when AL/QL/PA/ST are present.

    Formulary listing elements

    Formulary coverage entries with tiering and utilization controls

    Formulary entry elements: Each formulary line includes the therapeutic class, drug name and presentation, tier assignment, and Drug Requirements/ILimits which may include QL (quantity limits), PA (prior authorization), AL (age limits), ST (step therapy), SP (specialty) and package/max‑fill constraints (e.g., package(s) per 180 days).

    Non‑FDA uses generally require PA as noted on certain lines.

    The formulary distinguishes brand and generic drugs and generally promotes generics as first‑line therapy. Preferred brand drugs are placed on intermediate tiers when clinically appropriate; specialty drugs are handled separately (often Tier 4) and may require specialty pharmacy fulfillment or additional authorization. As a prescribing and billing reference, tier assignments, quantity limits, prior authorization and step therapy flags determine coverage and member cost sharing—verify member benefits for plan‑specific limits.

    Within this excerpt there are no explicit exclusion statements identifying broad product categories or clinical conditions that are excluded from coverage. Formulary entries instead indicate product-level controls (tier, QL, PA, AL) rather than a blanket exclusion policy.

    The extract does not contain explicit clinical exclusions (for example diagnoses or clinical situations that make drugs not covered). Coverage constraints shown are administrative (quantity limits, age limits, prior authorization, step therapy) applied at the product or presentation level.

    Certain nitrofurantoin/macrocrystal entries in the excerpt include corrupted text but clearly indicate a restricted coverage intent: the lines state the product is "Covered for malaria treatment only" with a subsequent fill-frequency limit (corrupted in the source). This indicates the formulation is restricted to a specific indication with limited fills.

    No explicit clinical exclusion language is present in this portion of the formulary extract. The document primarily records product-level utilization controls (PA, QL, AL, ST) rather than blanket exclusion determinations.

    Some topical products are subject to infrequent refill rules that functionally limit access—for example, clotrimazole topical entries include a "Limit 1 Fill per 180 days" or similar per‑180‑day maximums in the ILimits field. These package/fill-frequency limits effectively prevent more frequent refills.

    The formulary indicates that non‑FDA approved uses require Prior Authorization. In practice this means prescribing a drug for an indication not FDA‑labeled for that product will generally require submission of a PA request and supporting documentation prior to coverage.

    Within the provided extract there are no explicit "Not Medically Necessary" (NMN) determinations or wording declaring specific uses as not medically necessary. The formulary uses administrative controls (QL, PA, AL, ST) rather than explicit NMN statements in this segment.

    A repeat review of the excerpt shows No explicit NMN statements are present. Coverage guidance is expressed via tiering and utilization management flags rather than NMN language.

    Across other portions of this extract there remain No explicit "Not Medically Necessary" determinations. Items are governed by QL/PA/ST/AL criteria and any denial rationale would reference failure to meet those requirements.

    The excerpt does not present explicit NMN conclusions for listed drugs. Instead, coverage restrictions are operationalized with PA, QL, AL, and ST designations; absence of required documentation or authorization may result in denial but does not appear in the excerpt as NMN wording.

    All opioid medications filled (limit applies cumulatively)
    Authorization for excessProviders may submit a Prior Authorization request for fills exceeding these limits
    Example quantity limits — representative QL examples
    Representative QL formatsExamples include QL(0.143 EA daily), QL(3.6 ML per 28 day(s) retail), package(s) per 180 day(s)
    Per‑day exampleQL(4 EA daily) — common for solid oral products
    Per‑period/package examplepackage(s) per 180 day(s) — used for some biologic starter kits
    New start supply limit — 7 day(s) initial supply example
    Initial supply limit7 day(s) initial supply for new starts
    ContextApplies to many opioid formulations identified as 'New starts limited to 7 day supply'
    Exception processFills beyond 7 days require Prior Authorization
    Example daily quantity limits — sample QL values
    Common daily QL examplesQL(4 EA daily); QL(2 EA daily); QL(0.146 ML daily)
    Injectable/ml exampleQL(0.146 ML daily) — used for small-volume parenteral presentations
    Patch/low‑unit exampleQL(0.34 EA daily) — appears for some transdermal opioid entries
    Quantity Limit examples — assorted QL examples
    Assorted QL examplesQL(4 EA daily); QL(900 ML per 30 day(s)); QL(6 ML daily); 5 package(s) per 30 days; QL(60 ML daily)
    Respiratory/inhalationbudesonide SUSP — QL(4 ML daily)
    Anticoagulant injenoxaparin SOLN IJ 300 MG/3ML — QL(6 ML daily)
    Examples of quantity limits (ondansetron/itraconazole/posaconazole)
    Ondansetron 4 mgQL(4 EA daily; 60 EA per fill retail)
    Itraconazole SOLNQL(20 ML daily)
    Posaconazole SUSPQL(20 ML daily)
    Age limit for XIFAXAN 200 mg — AL example
    XIFAXAN 200 mg age limitAt least 12 yrs old
    Associated QLQL(3 EA; 9 EA per 3 day(s) retail; 9 EA per 3 days mail)
    Prior authorizationPA required for XIFAXAN entries as indicated
    Malaria treatment fill interval — 1 fill every 180 days example
    Malaria treatment fill intervalLimit 1 fill every 180 days for specified antimalarials (e.g., atovaquone-proguanil)
    Per‑fill QLQL(12 EA per fill retail; 12 per fill mail)
    Coverage noteCovered for malaria treatment only (per formulary lines)
    Sample QL numeric examples — assorted numeric QL examples
    Sample numeric QL examplesQL(0.143 EA daily); QL(2 EA daily); QL(1 EA daily); QL(8 EA daily)
    Biologic/low‑unit exampleQL(0.0089 EA daily) — used for select biologic presentations
    Antineoplastic numeric examplesQL(4 EA daily); QL(30 EA daily) shown for various oncology agents
    Age limits (AL) — examples of age restrictions
    Topical age limits examplesAL(At least 12 yrs old); AL(Up to 30 yrs) — applied to benzoyl peroxide and clindamycin topical entries
    Pediatric examplesSome oral/topical products list AL(At least 6 yrs old) or AL(At least 10 yrs old)
    Apply with QLAge limits must be met alongside QL/PA conditions for coverage
    Quantity limits (QL) — contraceptive/other QL examples
    Contraceptive/topical QL examplesLimit 1 Fill per 180 days (clotrimazole topical); QL(3 GM daily) or QL(2 ML daily) on topical formulations
    TWIRLA / transdermal9 EA per 84 days (example for transdermal contraceptive)
    ANNOVERA / vaginalCombination contraceptives vaginal — QL(3 EA daily) indicated in lines
    Age restrictions (AL) — topical age ranges
    Topical age rangesAL(At least 12 yrs old Up to 30 yrs old) shown for acne/topical agents
    Step therapy flagsSome topical combinations (e.g., clindamycin‑tretinoin) are flagged ST — step therapy may apply
    PA flagsSelected topical formulations include PA when noted (e.g., clindamycin topical FOAM)
    Quantity limits (QL) — topical/other multi‑valued QL examples
    Topical/multi QL examplesCOSENTYX entries: QL(0.072 ML daily) or QL(0.036 ML daily); benzoyl peroxide: QL( GM daily)
    Package/per‑fill limitsSome biologic/specialty products list package(s) per fill or per 180 days
    Max fill frequencyExamples include 1 max fill(s) per 180 days retail for select topical/biologic presentations
    Examples of quantity limits — miscellaneous QL examples
    Miscellaneous QL examplesvancomycin hcl CAPS — QL(4 EA daily; 40 EA per fill retail); XIFAXAN 200 mg — QL(3 EA per 3 days); prostacyclin agents — QL and PA noted
    Per‑fill retail examples40 EA per fill retail (example for vancomycin capsules)
    Specialty PASome specialty injectables listed with PA/SP which affect allowable QL

    PA for Specialty, Biologic, Antineoplastic, Pulmonary Hypertension, and Antiviral Agents

    Many specialty, biologic, oncology, pulmonary hypertension, antiviral, insulin, and other high-cost or specialty agents are designated as requiring PA and/or specialty (SP) processing. Requests for these drugs commonly require submission of prior therapy history, dosing regimen, and anticipated duration. Non-FDA uses (off-label) also generally require PA documentation.

    • Biologics and biosimilars listed with 'PA' require prior authorization; examples throughout the formulary include adalimumab products, monoclonal antibodies, and oncology agents (many of which are also SP).
    • Antineoplastics and adjunctive cancer therapies flagged 'SP; PA' require specialty-channel processing plus PA.
    • Pulmonary hypertension therapies and prostacyclin agents (e.g., treprostinil, epoprostenol, riociguat, bosentan-related entries) are often SP and PA.
    • Select antivirals and hepatitis/HIV agents may have QL, refill-frequency limits, and PA; e.g., tenofovir products and certain combination antiviral regimens are flagged SP; PA or PA with limits.
    • Non-FDA (off-label) uses require PA.
    Denial Risk

    PA and Quantity Limits for Opioids

    Opioid products frequently carry both PA and quantity limits. New starts for many opioid formulations are limited to a 7-day supply unless documented justification for an exception is provided. Requests that exceed quantity limits or do not have required PA documentation may be denied.

    • New starts limited to 7-day supply for many immediate-release opioid liquid and tablet products — document rationale for exceptions.
    • Common opioid QL examples: hydrocodone and hydromorphone entries include daily QLs (e.g., QL(2 EA daily)) and may require PA.
    • Requests exceeding the stated QL (quantity limit) or without an approved PA are at high risk for denial—provide documentation to support medical necessity for amounts beyond the QL.
    • Naloxone and certain opioid antidotes have specific per-fill and per-period QLs and may be Rx/OTC noted; some naloxone presentations also list PA for certain uses.
    Documentation Required

    Quantity, Age, and Fill/Package Limit Requirements

    Quantity limits (QL), age limits (AL), fill/package frequency limits, and specialty (SP) designations are applied across the formulary. When a product lists a QL, AL, or refill frequency limit (for example, 1 max fill per 90 days or package limits per 180 days), the provider must document the clinical justification for exception requests. Exceeding those limits without supporting documentation or required PA may result in a denial.

    • Document intended days supply, units per day, and reason for exceeding the QL when requesting an exception.
    • Fill/package limits: several products list limits per 30/90/180/365 days — verify the product entry and include requested frequency in PA.
    • Requests that exceed QL/AL/packaging limits without sufficient clinical justification or an approved PA are likely to be denied.
    Prior Authorization

    PA for Select Insulin and Specialty Diabetes Agents

    Certain insulin and specialty diabetes agents are designated as PA and/or have quantity limits. For these products, clinical documentation should include prior therapies tried (including formulary insulins), current A1c or relevant glucose data, and the specific insulin product/dosing requested.

    • Select insulin products (e.g., concentrated U-500, pen/cartridge systems, long-acting/high-cost pens) may require PA (see formulary entries like HUMULIN R U-500, REZVOGLAR, TRESIBA FlexTouch entries).
    • Combination/extended-release antidiabetic products may have QL and PA requirements (e.g., TRIJARDY, SYNJARDY XR, XULTOPHY).
    • Include glycemic control data, prior agent trials, and quantity/dosing when submitting PA for insulin or specialty diabetes agents.
    Step Therapy

    Step Therapy (ST) Requirements

    Some formulary entries list Step Therapy (ST) requirements, while others do not enumerate explicit step sequences in the excerpt. Where ST is indicated, providers must document trials of required preferred agents before requesting the non-preferred or step-exempt product.

    • Examples in the formulary show ST flags for certain topical and combination products; follow the plan's ST process when present.
    • When ST is not detailed in the formulary excerpt, contact the payer for the required prior agent(s) or review the plan's step-therapy matrix.
    • Site-of-care or specialty program indicators (SP) may interact with ST; for example, some injectables require SP processing even if ST is applicable.
    Denial Risk

    Specialty Injectables — PA/SP Risk

    Specialty injectables and high-cost biologics commonly require both PA and specialty dispensing (SP). These products have heightened denial risk if SP or PA requirements are not satisfied.

    • Examples include antineoplastics, monoclonal antibodies, growth hormones, ACTHAR GEL, teriparatide, zoledronic acid, and many biosimilars marked 'PA' or 'SP; PA'.
    • Confirm specialty channel availability and include provider/site enrollment info if required by the specialty program when submitting PA.
    • Failure to meet SP contracting/dispensing requirements or to obtain PA may result in claim denial or coverage refusal.
    Prior Authorization

    PA Required for Specific Products

    Certain individual products are specifically flagged with PA in the formulary (examples include SPRAVATO, select antifungals/antivirals, XIFAXAN, select antidiabetics, and many biologics). Providers should check the formulary entry before prescribing and initiate PA when indicated.

    • SPRAVATO (56 mg and 84 mg doses) is listed with PA; the 84 mg dose also lists a QL (1 EA daily) plus PA — include dosing frequency and treatment setting in the PA.
    • Antifungals like itraconazole, posaconazole, voriconazole include QL/PA entries — include indication and prior therapy in PA.
    • XIFAXAN (200 mg and 550 mg) lists age limits and PA — document age and indication.
    • Many biologic agents (adalimumab variants, et al.) list PA and package/180-day fill limits; include prior biologic exposure and rationale.
    Documentation Required

    PA Documentation Expectations

    Documentation that should accompany PA requests includes: indication/diagnosis, relevant lab or imaging data, prior medication trials (and why they failed or were not tolerated), patient age for AL rules, and the exact quantity/days supply requested. This documentation supports approval and any exception to QL/AL limits.

    • Suggested documentation elements: diagnosis/indication, prior therapy history (dates, doses, response), objective measures (A1c, viral load, etc.), patient age if AL applies, and requested quantity/days supply.
    • For quantity exceptions, provide clinical rationale tied to dosing needs (weight-based dosing, titration, or extended supplies).
    • If requesting coverage for non-FDA or off-label uses, include literature support and treating specialist documentation.
    Denial Risk

    Denial Risk and Explanation

    Requests that exceed quantity limits, age limits, or that lack required PA or specialty processing may be denied. Denial notices will specify reasons and identify missing documentation when applicable. Providers should include follow-up contact info and be prepared to submit peer-to-peer or appeal information per payer processes.

    • Denials commonly cite lack of PA, exceeding QL, age outside AL, missing prior therapy trials (ST), or missing clinical information.
    • If a request is incomplete, the denial/explanation will identify exactly what additional information is required to complete the PA.
    • Providers may be given next steps for appeal or resubmission — include clear clinical justification on re-submission to address stated denial reasons.
    Billing Rule

    Prior Authorization Triggers — Operational Reminder

    Operational/billing triggers — prior authorization must be obtained before dispensing for listed drugs; PA and QL indicators in the formulary constitute triggers for prior authorization submission.

    • Check formulary entries for the 'PA', 'QL', 'AL', 'SP', and 'ST' flags prior to prescribing/dispensing.
    • When a product is labeled 'PA' in the formulary, do not assume auto-coverage — submit PA prior to claim submission to avoid denial.
    • Some products additionally list refill frequency limits (e.g., 1 max fill per 90 days); adhere to these operational limits or secure PA with justification.
    7 days for new starts

    Limit applies cumulatively across opioid products; providers should submit PA for exceptions.

    Agent / ExampleTierILimits (example)Policy implication
    Tier 2
    Examples include QL(0.143 ML daily); PA on select presentations
    Tier 1B; some entries show ILimits = ST or QL(1 EA daily)
    Tiering plus ILimits identify preferred agents and PA triggers though step sequences are not detailed here
    Combination productST flagExample ILimitsNotes
    ST
    ST; QL(1 EA daily)
    ST on some lines
    Some combination products are specifically marked 'ST' in ILimits
    Antineoplastic agentTier / DesignationSP / PA flagNotes
    Tier 4
    Listed as 'SP; PA' in ILimits
    SP; PA indicated on multiple agents
    SP designation indicates specialty processing and PA commonly required for oncology agents
    Drug / ClassST or SPExample ILimitsNotes
    ST; QL(A EA daily)
    ST; QL(2 EA daily)
    Some entries show ST or SP; PA may apply
    Apomorphine and bromocriptine examples show explicit ST flags in ILimits
    ProductFormulationST flagILimits / Note
    SOCT presentation
    ILimits include QL(A EA daily); ST indicated
    Entry explicitly lists 'ST' — step therapy required prior to coverage
    Formulary line shows 'apomorphine hydrochloride SOCT ... ILimits = QL(A EA daily); ST'
    ProductFormulationST flagILimits / Note
    Capsule presentations
    Drug Requirements/ILimits include 'ST'
    Some bromocriptine lines show QL(2 EA daily)
    Step therapy flagged for bromocriptine in formulary ILimits
    ObservationDetailST sequences specified?Action
    Formulary lines include tier assignments across products
    Not specified in this extract; ST flags referenced without ordered steps
    When ST flags exist, providers should refer to full plan rules or PA requirements for sequence details
    Summary based on multiple formulary lines in excerpt
    ProductFormulationST flagNotes
    Oral suspension presentations
    Formulary ILimits reference ST for cefixime suspension
    Step therapy required as indicated in ILimits field
    Formulary entry notes 'ILimits = ST' for cefixime suspension in excerpt
    Topical productFormulation / TierST flagILimits / Notes
    Topical combination; Tier 1B–2 depending on line
    ILimits show 'ST' for clindamycin phosphate-tretinoin in formulary lines
    Tier 3; ILimits = AL(At least 12 yrs old); PA; QL(15 GM per 30 days)
    Multiple corticosteroid and calcipotriene combinations flagged ST in ILimits
    Therapeutic groupPA present?SP present?ST details provided?
    PA
    PA; SP on some lines
    SP; PA indicated; step specifics not provided in excerpt
    PA and SP are indicated for several specialty classes though explicit step therapy sequences are not specified here
    Limit applies cumulatively to all opioid medications filled
    Provider actionSubmit PA for fills exceeding limits
    ADALIMUMAB biosimilars (selected presentations) — QL/package‑per‑180‑day examples
    Adalimumab biosimilars QL exampleQL(0.143 EA daily) or package(s) per 180 day(s)
    Package limitpackage(s) per 180 day(s) retail/mail for certain starter kit presentations
    PA requirementPA indicated for many adalimumab biosimilar presentations
    ACTEMRA SOLN — QL per 28‑days retail/mail example
    ACTEMRA SOLN QLQL(3.6 ML per 28 day(s) retail; 4 ML per 28 days mail) — example ILimits for ACTEMRA SOLN
    Specialty flagSP indicated for some ACTEMRA presentations
    PA notePA may apply as noted in product line
    Multiple opioid products QL examples — assorted daily/ML limits
    Multiple opioid QL examplesExamples include QL(4 EA daily); QL(2 EA daily); QL(0.34 EA daily); QL(0.146 ML daily); QL(100 ML daily)
    PA guidanceMany opioid product lines also list PA where indicated
    New‑start notation'New starts limited to 7 day supply' appears across multiple opioid entries
    ANDRODERM PT24 QL example
    ANDRODERM PT24 QLQL(1 EA daily)
    PA flagPA indicated on some ANDRODERM entries
    Per‑period fill noteSome androgen entries include per‑retail fill limits (e.g., 9 EA per retail per 75 days)
    Alprazolam tabs QL example (4 EA daily)
    Alprazolam tabs QLQL(4 EA daily)
    Strengths includedApplies to 0.25 mg, 0.5 mg, 1 mg presentations as listed
    PA where notedSome formulations include PA/other ILimits per line
    Nitroglycerin intra‑anal QL example
    Nitroglycerin intra‑anal QLQL(2 GM daily)
    Formulation noteApplies to intra‑anal nitroglycerin formulations listed in segment
    TieringTier assignments vary by presentation — check product line
    Budesonide inhalation suspension QL example
    Budesonide inhalation suspension QLQL(4 ML daily)
    PA indicatedLine shows PA alongside QL for some presentations
    Retail/mail distinctionILimits may differ retail vs mail on other inhaled products
    Rivaroxaban suspension QL example
    Rivaroxaban suspension QLQL(900 ML per 30 day(s))
    Product classApplies to rivaroxaban SUSR 1 MG/ML suspension presentations
    Per‑period basisLarge‑volume suspension QL expressed per 30 days
    Enoxaparin SOLN IJ QL example
    Enoxaparin SOLN IJ QLQL(6 ML daily)
    Multiple concentrationsDifferent SOSY/SOLN presentations show varying ML/day QLs (e.g., 1.6 ML daily, 2 ML daily)
    PA/SP notesSome enoxaparin lines include PA or SP flags depending on presentation
    Diazepam gel / NAYZILAM / VALTOCO QL examples
    Diazepam gel QL5 package(s) per 30 days (retail and mail)
    NAYZILAM exampleQL(10 EA per 30 days retail); PA indicated
    VALTOCO dose exampleVALTOCO 15 mg dose: QL(60 ML daily) shown for some presentations
    Topiramate 200 mg / zonisamide / vigabatrin QL examples
    Topiramate 200 mg QLQL(2 EA daily)
    Zonisamide QLQL(6 EA daily)
    Vigabatrin QLQL(6 EA daily); SP; PA for some presentations
    Vilazodone / GLYXAMBI / HUMULIN R U‑500 QL examples
    Vilazodone QLQL(2 EA daily)
    GLYXAMBI QLQL(1 EA daily)
    Insulin U‑500 QLHUMULIN R U‑500 SOLN SC — QL(1.34 ML daily)
    Naloxone and ondansetron QL examples
    Naloxone liquid QLQL(2 EA per retail); 2 max fills per 30 days (retail)
    Ondansetron 8 mg QLQL(3 EA daily; 45 EA per fill retail)
    Ondansetron 4 mg QLQL(4 EA daily; 60 EA per fill retail)
    Itraconazole CAPS / SOLN and posaconazole suspension QL examples
    Itraconazole CAPS QLQL(4 EA daily)
    Itraconazole SOLN QLQL(20 ML daily)
    Posaconazole SUSP QLQL(20 ML daily)
    Posaconazole / voriconazole / cetirizine QL examples
    Posaconazole SUSP QLQL(20 ML daily)
    Voriconazole TABS QLQL(4 EA daily)
    Cetirizine QLsQL(1 EA daily) or QL(6 EA daily) depending on entry
    Fenofibrate / rosuvastatin / REPATHA QL + PA examples
    Fenofibrate QLQL(1 EA daily)
    Rosuvastatin QLQL(1 EA daily)
    REPATHA PUSHTRONEX / SURECLICKQL(0.25 ML daily) and QL(0.0714 ML daily) respectively; PA required
    Benazepril & HCTZ / vancomycin / oncology QL range examples
    Benazepril & HCTZ QL rangeQL(1–4 EA daily) depending on specific line
    Vancomycin capsules QLQL(4 EA daily; 40 EA per fill retail)
    Oncology QL examplesMultiple oncology agents show small EA/day QLs (e.g., QL(0.143 EA daily))
    Digoxin / nebivolol / contraceptive QL examples
    Digoxin daily limitQL(2 EA daily)
    Nebivolol 20 mgQL(2 EA daily)
    TWIRLA / norelgestromin‑ethinyl estradiolExample: 9 EA per 84 days (transdermal), QL(1 EA daily class note)
    Note